SEC Form 4 · accession 0000899243-16-028294
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shlomo Yanai
Director
Period of report
Aug 29, 2016
Accepted (ET)
Aug 31, 2016 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 29, 2016 | D | 742 | $21.75 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F2,F3 | — | Aug 29, 2016 | D | 8,556 | D | — | — | Common Stock | 8,556 | 0 | D |
| Restricted Stock UnitsF4,F2,F5 | — | Aug 29, 2016 | D | 2,228 | D | — | — | Common Stock | 2,228 | 0 | D |
Explanation of responses
- F1Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").
- F2Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
- F3The restricted stock units provided for vesting on February 22, 2017.
- F4Each restricted stock unit was disposed pursuant to the Merger Agreement whereby each such restricted stock unit was cancelled and converted into the right to receive the Merger Consideration.
- F5The restricted stock units provided for vesting in four equal annual installments beginning on April 15, 2016.